Using its novel discovery platform, FivePrime is building a strong pipeline of oncology and immunology drug candidates. FivePrime mines its comprehensive library of secreted and exracellular human proteins to screen for medically relevant new therapeutic proteins and antibody targets. GlaxoSmithKline has the rights to develop and commercialize FivePrime's lead product, FP-1039, in the United States, Canada, and the EU. FivePrime has also established significant collaborations for the discovery of innovative biologics in specific thrapeutic areas with several leading pharmaceutical companies, including Pfizer, Centocor, Boehringer Ingelheim, GlaxoSmithKline and UCB.